1. Dipòsit Digital de la Universitat de Barcelona
  2. Recerca
  3. Bioquímica i Biomedicina Molecular
  4. Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/158439
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCarpéné, Christian-
dc.contributor.authorGarcia-Vicente, Silvia-
dc.contributor.authorSerrano, Marta-
dc.contributor.authorMartí, Luc-
dc.contributor.authorBelles, Chloé-
dc.contributor.authorRoyo Expósito, Miriam-
dc.contributor.authorGalitzky, Jean-
dc.contributor.authorZorzano Olarte, Antonio-
dc.contributor.authorTestar, Xavier-
dc.date.accessioned2020-05-03T12:16:58Z-
dc.date.available2020-05-03T12:16:58Z-
dc.date.issued2017-04-15-
dc.identifier.issn1948-9358-
dc.identifier.urihttp://hdl.handle.net/2445/158439-
dc.description.abstractThis study investigates in murine and human adipocytes the antilipolytic properties of a conjugate of benzylamine and decavanadate (B6V10), already reported to lower hyperglycaemia in diabetic rodents. Data indicated that the conjugate dose-dependently inhibited submaximal activation of lipolysis in all the species studied. Such antilipolytic action deals with the in vivo FFA-lowering properties already described for B6V10 in diabetic rats. B6V10 also activated lipogenesis and glucose transport in fat cells. B6V10 should therefore be useful in preventing the lipotoxicity constituted by the unrestrained lipolytic activity of insulin-resistant adipocytes in obese individuals presenting type 2 diabetes, a state named diabesity.-
dc.format.extent11 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBaishideng Publishing Group Inc-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.4239/wjd.v8.i4.143-
dc.relation.ispartofWorld Journal of Diabetes, 2017, vol. 8, num. 4, p. 143-153-
dc.relation.urihttps://doi.org/10.4239/wjd.v8.i4.143-
dc.rightscc-by-nc (c) Carpéné, Christian et al., 2017-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es-
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)-
dc.subject.classificationTeixit adipós-
dc.subject.classificationResistència a la insulina-
dc.subject.classificationObesitat-
dc.subject.otherAdipose tissues-
dc.subject.otherInsulin resistance-
dc.subject.otherObesity-
dc.titleInsulin-mimetic compound hexaquis (benzylammonium) decavanadate is antilipolytic in human fat cells-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec672268-
dc.date.updated2020-05-03T12:16:59Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid28465791-
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Files in This Item:
File Description SizeFormat 
672268.pdf1.32 MBAdobe PDFView/Open
Show simple item record


This item is licensed under a Creative Commons License Creative Commons